Based on the promising preliminary data, PIPAC might become an additional therapeutic option for the palliative local treatment of pmCRC in the future. Moreover, it might be interesting as a neoadjuvant local treatment with or without the addition of systemic chemotherapy beyond CRS and HIPEC.Several prospective clinical trials evaluating this therapy approach are ongoing.The results may help to determine the role of PIPAC within a multidisciplinarytreatment concept and allow for further improvement of patient selection. Other indications for PIPAC in CPM, including as a prophylactic, neoadjuvant or adjuvant therapy, might be evaluated in the future.